Patent ID: 9526725
Filing Date: 2016-12-27
CPC Classification: A61K,A61P

Claim Text:
1. A method for alleviating or reducing the frequency or incidence of at least one acute symptom of a vestibular disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a selective Histamine H4 receptor antagonist, wherein the selective Histamine H4 receptor antagonist comprises a pyrimidin structure, a methylpiperazin structure, or a quinazolin structure, is 1-[(5-chloro-1H-benzimidazol-2-yl)carbonyl]-4-methylpiperazine, 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine, 4-((3R)-3-Aminopyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine, cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine, 2-isobutyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-4-amine, N 4 -(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine or (R)-4-(3-Amino-pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine, and has a K